Literature DB >> 20869564

Clinical, histopathologic, and radiographic indicators of malignancy in head and neck paragangliomas.

D Brandon Chapman1, Dylan Lippert, Carol P Geer, Henry D Edwards, Gregory B Russell, Catherine J Rees, J Dale Browne.   

Abstract

OBJECTIVE: The goal of this study is to review our series of head and neck paragangliomas to identify factors that may help in predicting malignancy. STUDY
DESIGN: Case series with chart review.
SETTING: Academic medical center. SUBJECTS AND METHODS: Subjects with head and neck paragangliomas at our institution from 1976 to current were reviewed. In addition to statistical comparisons of epidemiologic factors, pathologic and radiographic characteristics were reviewed.
RESULTS: Of the 84 subjects, there were seven malignant paragangliomas (8%). Age was found to be significantly different between the benign and malignant subgroups, with an average age of 54 ± 16 and 40 ± 12 years, respectively (P = 0.02). Pain was a presenting complaint in five patients with benign disease (6%), and five of the seven malignant patients (71%) presented with pain, showing a significant association between pain and disease type (P < 0.0001). The odds ratio for a patient with pain having a malignant tumor was 36 (95% CI: 5.5-234). Enlarging neck mass was noted in all cases of malignant disease, but only in 31 percent of cases of benign disease (P < 0.0001). In a secondary analysis of carotid body tumors alone, enlarging neck mass was not found to be significant between benign and malignant disease (P = 0.14). However, pain continued to be significantly different, with 67 percent of malignant lesions demonstrating pain, compared with only 11 percent of benign lesions (P = 0.01).
CONCLUSION: This study suggests that pain, a rapidly enlarging neck mass, and younger age are predictive factors of underlying malignancy, which should prompt one to consider an aggressive diagnostic and management approach.
Copyright © 2010 American Academy of Otolaryngology–Head and Neck Surgery Foundation. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20869564     DOI: 10.1016/j.otohns.2010.05.031

Source DB:  PubMed          Journal:  Otolaryngol Head Neck Surg        ISSN: 0194-5998            Impact factor:   3.497


  6 in total

1.  Preoperative embolization of carotid chemodectoma: a technical challenge that can be customized according to angioarchitecture. Illustrative cases.

Authors:  Giuseppe Faragò; Carlotta Castellani; Silvano Ponzi; Claudio Jankovic; Vittorio Saginario; Carlo Berardi; Bianca Pollo; Elisa F Ciceri
Journal:  Neuroradiol J       Date:  2013-12-18

Review 2.  Diagnostic tests and biomarkers for pheochromocytoma and extra-adrenal paraganglioma: from routine laboratory methods to disease stratification.

Authors:  Graeme Eisenhofer; Arthur S Tischler; Ronald R de Krijger
Journal:  Endocr Pathol       Date:  2012-03       Impact factor: 3.943

3.  A Four-Generational Report on Hereditary Head and Neck Paraganglioma.

Authors:  Mihnea Cristian Trache; Julian Bewarder; Christian Stephan Betz; Nikolaus Möckelmann; Arne Böttcher
Journal:  Cureus       Date:  2022-04-14

4.  Local Tumor Behavior Associated With Survival Among Patients With Paraganglioma of the Head and Neck.

Authors:  Randall J Harley; Jason H Lee; Benjamin T Ostrander; Andrey Finegersh; Tammy B Pham; Kareem O Tawfik; Yin Ren; Farhoud Faraji; Rick A Friedman
Journal:  OTO Open       Date:  2022-03-31

5.  Jugulotympanic paraganglioma: a rare cause of vertigo.

Authors:  Asad Jehangir; Ranjan Pathak; Bilal Shaikh; Ahmed Salman; Shoaib Bilal Fareedy; Anam Qureshi; Qasim Jehangir; Richard Alweis
Journal:  Am J Case Rep       Date:  2015-04-18

Review 6.  Giant carotid chemodectoma treated with a combination of surgery and CyberKnife radiotherapy: a case report and review of the literature.

Authors:  José M López-Arcas; César M Colmenero; Roberto Martínez; Fátima Martín-Hernán; Beatriz Ruiz-Sánchez; Juan Manuel Aragoneses
Journal:  J Med Case Rep       Date:  2022-02-25
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.